clofazimine has been researched along with Multiple Myeloma in 2 studies
Clofazimine: A fat-soluble riminophenazine dye used for the treatment of leprosy. It has been used investigationally in combination with other antimycobacterial drugs to treat Mycobacterium avium infections in AIDS patients. Clofazimine also has a marked anti-inflammatory effect and is given to control the leprosy reaction, erythema nodosum leprosum. (From AMA Drug Evaluations Annual, 1993, p1619)
clofazimine : 3-Isopropylimino-3,5-dihydro-phenazine in which the hydrogen at position 5 is substituted substituted by a 4-chlorophenyl group, and that at position 2 is substituted by a (4-chlorophenyl)amino group. A dark red crystalline solid, clofazimine is an antimycobacterial and is one of the main drugs used for the treatment of multi-bacillary leprosy. However, it can cause red/brown discolouration of the skin, so other treatments are often preferred in light-skinned patients.
Multiple Myeloma: A malignancy of mature PLASMA CELLS engaging in monoclonal immunoglobulin production. It is characterized by hyperglobulinemia, excess Bence-Jones proteins (free monoclonal IMMUNOGLOBULIN LIGHT CHAINS) in the urine, skeletal destruction, bone pain, and fractures. Other features include ANEMIA; HYPERCALCEMIA; and RENAL INSUFFICIENCY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Clofazimine (CLF) is an FDA-approved leprostatic, anti-tuberculosis, and anti-inflammatory drug that was previously shown to have growth suppression effect on various cancer types such as hepatocellular, lung, cervix, esophageal, colon, and breast cancer as well as melanoma, neuroblastoma, and leukemia." | 5.46 | Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line. ( Ataş, H; Biber, A; Durusu, İZ; Gerekçi, S; Güleç, EA; Hüsnügil, HH; Özen, C, 2017) |
| "In patients with multiple myeloma (MM), AHR levels were inversely correlated with survival, suggesting that AHR inhibition may be beneficial for the treatment of this disease." | 1.48 | Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma. ( Affronti, HC; Bagati, A; Bergsagel, PL; Bianchi-Smiraglia, A; Fink, EE; Gitlin, II; Gudkov, AV; Han, Z; Kandel, ES; Lee, KP; Leonova, KI; Lightman, SM; Lipchick, BC; Long, MD; Moparthy, K; Moparthy, S; Nikiforov, MA; Polechetti, A; Roll, MV; Rosario, SR; Rowsam, AM; Smiraglia, DJ; Wolff, DW; Yun, DH, 2018) |
| "Clofazimine (CLF) is an FDA-approved leprostatic, anti-tuberculosis, and anti-inflammatory drug that was previously shown to have growth suppression effect on various cancer types such as hepatocellular, lung, cervix, esophageal, colon, and breast cancer as well as melanoma, neuroblastoma, and leukemia." | 1.46 | Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line. ( Ataş, H; Biber, A; Durusu, İZ; Gerekçi, S; Güleç, EA; Hüsnügil, HH; Özen, C, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bianchi-Smiraglia, A | 1 |
| Bagati, A | 1 |
| Fink, EE | 1 |
| Affronti, HC | 1 |
| Lipchick, BC | 1 |
| Moparthy, S | 1 |
| Long, MD | 1 |
| Rosario, SR | 1 |
| Lightman, SM | 1 |
| Moparthy, K | 1 |
| Wolff, DW | 1 |
| Yun, DH | 1 |
| Han, Z | 1 |
| Polechetti, A | 1 |
| Roll, MV | 1 |
| Gitlin, II | 1 |
| Leonova, KI | 1 |
| Rowsam, AM | 1 |
| Kandel, ES | 1 |
| Gudkov, AV | 1 |
| Bergsagel, PL | 1 |
| Lee, KP | 1 |
| Smiraglia, DJ | 1 |
| Nikiforov, MA | 1 |
| Durusu, İZ | 1 |
| Hüsnügil, HH | 1 |
| Ataş, H | 1 |
| Biber, A | 1 |
| Gerekçi, S | 1 |
| Güleç, EA | 1 |
| Özen, C | 1 |
2 other studies available for clofazimine and Multiple Myeloma
| Article | Year |
|---|---|
Inhibition of the aryl hydrocarbon receptor/polyamine biosynthesis axis suppresses multiple myeloma.
Topics: Animals; Biogenic Polyamines; Cell Line, Tumor; Clofazimine; HEK293 Cells; Humans; Mice; Multiple My | 2018 |
Anti-cancer effect of clofazimine as a single agent and in combination with cisplatin on U266 multiple myeloma cell line.
Topics: Antineoplastic Agents; Apoptosis; Cell Line, Tumor; Cell Proliferation; Cisplatin; Clofazimine; Drug | 2017 |